tbuckley/cabot-search huggingface dataset:
Nasal neuron PET imaging quantifies neuron generation and degeneration
Authors: Genevieve C. Van de Bittner, Misha M. Riley, Luxiang Cao, Janina Ehses, Scott P. Herrick, Emily L. Ricq, Hsiao-Ying Wey, Michael J. O’Neill, Zeshan Ahmed, Tracey K. Murray, Jaclyn E. Smith, Changning Wang, Frederick A. Schroeder, Mark W. Albers, Jacob M. Hooker
Journal: Journal of Clinical Investigation (2017)

Olfactory dysfunction is broadly associated with neurodevelopmental and neurodegenerative diseases and predicts increased mortality rates in healthy individuals. Conventional measurements of olfactory health assess odor processing pathways within the brain and provide a limited understanding of primary odor detection. Quantification of the olfactory sensory neurons (OSNs), which detect odors within the nasal cavity, would provide insight into the etiology of olfactory dysfunction associated with disease and mortality. Notably, OSNs are continually replenished by adult neurogenesis in mammals, including humans, so OSN measurements are primed to provide specialized insights into neurological disease. Here, we have evaluated a PET radiotracer, [11C]GV1-57, that specifically binds mature OSNs and quantifies the mature OSN population in vivo. [11C]GV1-57 monitored native OSN population dynamics in rodents, detecting OSN generation during postnatal development and aging-associated neurodegeneration. [11C]GV1-57 additionally measured rates of neuron regeneration after acute injury and early-stage OSN deficits in a rodent tauopathy model of neurodegenerative disease. Preliminary assessment in nonhuman primates suggested maintained uptake and saturable binding of [18F]GV1-57 in primate nasal epithelium, supporting its translational potential. Future applications for GV1-57 include monitoring additional diseases or conditions associated with olfactory dysregulation, including cognitive decline, as well as monitoring effects of neuroregenerative or neuroprotective therapeutics.
In older adults with COPD, new opioid use was linked to increased risk for respiratory and all-cause mortality
Authors: Mitchell Levine
Journal: Annals of Internal Medicine (2017)

ACP Journal Club17 January 2017In older adults with COPD, new opioid use was linked to increased risk for respiratory and all-cause mortalityMitchell Levine, MDMitchell Levine, MDMcMaster University, Hamilton, Ontario, Canada (M.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-166-2-011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationVozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;48:683-93. https://pubmed.ncbi.nlm.nih.gov/27418553Clinical Impact RatingsGIM/FP/GP: Pulmonology: Author, Article, and Disclosure InformationAffiliations: McMaster University, Hamilton, Ontario, Canada (M.L.)This article was published at Annals.org on 3 January 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAn Analysis of Primary Care Clinician Communication About Risk, Benefits, and Goals Related to Chronic Opioid Therapy 17 January 2017Volume 166, Issue 2Page: JC11KeywordsChronic obstructive pulmonary diseaseDrugsElderlyHazard ratioHospitalizationsIntensive care unitsMortalityOpioidsOutpatientsPneumonia ePublished: 17 January 2017 Issue Published: 17 January 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The New Italian Mastocytosis Registry.
Authors: Serena Merante, Diomira Magliacane, Iria Neri, Cristiana Pascutto, Roberta Zanotti, Ingeborg Forer, Lisa Pieri, Paolo Fabbri, Anna Belloni Fortina, Ilaria Romano, Marina Mauro, Martinelli Giovanni, Michela Rondoni, Elena Guggiari, Sergio Di Nuzzo, Gianfranco Altomare, Matteo Ferrari Dagrada, Triggiani Massimo
Journal: Blood (2010)
Increased Prevalence of Anti-CD36 and Elevated Endothelial Microparticles in Patients with Recurrent Thrombosis.
Authors: Carlos J. Bidot, Wenche Jy, Camile Ortega, Larry L. Horstman, Carlos Bidot, Loreta Bidot, Cynthia Petit, Vincenzo Fontana, Miriam Yaniz, Yeon-Soong Ahn
Journal: Blood (2007)
A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts
Authors: Jesus G. Berdeja, Tara B. Gregory, Edward A. Faber, Jeffrey V. Matous, Lowell L. Hart, Joseph R. Mace, James D. Peyton, James H. Essell, Edward R. Arrowsmith, Ian W. Flinn
Journal: Blood (2015)
Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation
Authors: Rafael Bejar, Kristen E. Stevenson, Petar Stojanov, J. Eric Zaneveld, Michal Bar-Natan, Bennett Caughey, Hui Wang, Guillermo Garcia-Manero, Hagop M. Kantarjian, Corey Cutler, Jerome Ritz, Kristian Cibulskis, Gad Getz, David P. Steensma, Richard M. Stone, Rui Chen, Donna S. Neuberg, Benjamin L. Ebert
Journal: Blood (2012)
Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,
Authors: Su Wai Maung, Denis O'Keeffe, Maeve Leahy, Hilary M O'Leary, Irfan Khan, Mary Cahill, Oonagh Galligan, Philip Murphy, Janusz Krawczyk, Suzanne McPherson, J F Jackson, Mary Ryan, Brian Hennessy, Aine C Burke, Helen Enright, Johnny McHugh
Journal: Blood (2011)
TRAF6 Dominant Negative Peptides Block Intracellular Signaling Resulting in Anti-Myeloma and Anti-Bone Resorptive Effects in Multiple Myeloma
Authors: Mingjie Li, Marissa P Dreyer, Cameryn P Ahles, David Ramirez, Cydney M Nichols, Tiffany Lee, More Song, Cathy S Wang, Eric Sanchez, Haiming Chen, Benjamin Bonavida, James R. Berenson
Journal: Blood (2011)
Gene Alterations In Acute Megakaryoblastic Leukemia (AMKL): a Comparison of AMKL with and without Down Syndrome
Authors: Asahito Hama, Hideki Makishima, Hideki Muramatsu, Yuka Sugimoto, Sayoko Doisaki, Akira Shimada, Yoshiyuki Takahashi, Hitoshi Kiyoi, Seiji Kojima, Jaroslaw P. Maciejewski
Journal: Blood (2010)
Long-Term Survival In Patients With Acute Steroid Refractory Graft-Versus-Host-Disease (SR-GVHD) Treated With Infliximab Combined With Daclizumab
Authors: Sanaz Nicky Soltani, Ramaprasad Srinivasan, Theresa Jerussi, A. John Barrett, Thomas E Hughes, Catalina Ramos, Lisa Cook, Elena Cho, Richard W. Childs
Journal: Blood (2013)
Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells
Authors: Sarah T. Boyle, Krystyna A. Gieniec, Carly E. Gregor, Jessica W. Faulkner, Shaun R. McColl, Marina Kochetkova
Journal: Molecular Cancer (2017)

Breast cancer is the major cause of cancer-related mortality in women. It is thought that quiescent stem-like cells within solid tumors are responsible for cancer maintenance, progression and eventual metastasis. We recently reported that the chemokine receptor CCR7, a multi-functional regulator of breast cancer, maintains the stem-like cell population. This study used a combination of molecular and cellular assays on primary mammary tumor cells from the MMTV-PyMT transgenic mouse with or without CCR7 to examine the signaling crosstalk between CCR7 and Notch pathways. We show for the first time that CCR7 functionally intersects with the Notch signaling pathway to regulate mammary cancer stem-like cells. In this cell subpopulation, CCR7 stimulation activated the Notch signaling pathway, and deletion of CCR7 significantly reduced the levels of activated cleaved Notch1. Moreover, blocking Notch activity prevented specific ligand-induced signaling of CCR7 and augmentation of mammary cancer stem-like cell function. Crosstalk between CCR7 and Notch1 promotes stemness in mammary cancer cells and may ultimately potentiate mammary tumor progression. Therefore, dual targeting of both the CCR7 receptor and Notch1 signaling axes may be a potential therapeutic avenue to specifically inhibit the functions of breast cancer stem cells.
Donor Leukocyte Infusions (DLIs) for Recurrent Hodgkin Lymphoma (HL) Following Allogeneic Stem Cell Transplantation (allo-SCT): Ten-Year Experience at the M.D. Anderson Cancer Center
Authors: Paolo Anderlini, Sandra Acholonu, Grace-Julia Okoroji, Sergio A Giralt, Roy Jones, Chitra M Hosing, Muzaffar H Qazilbash, Yago Nieto, Borje S Andersson, Uday R Popat, Naoto T Ueno, Marcos J de Lima, Richard E Champlin
Journal: Blood (2011)
An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis
Authors: Slavé Petrovski, Jamie L. Todd, Michael T. Durheim, Quanli Wang, Jason W. Chien, Fran L. Kelly, Courtney Frankel, Caroline M. Mebane, Zhong Ren, Joshua Bridgers, Thomas J. Urban, Colin D. Malone, Ashley Finlen Copeland, Christie Brinkley, Andrew S. Allen, Thomas O’Riordan, John G. McHutchison, Scott M. Palmer, David B. Goldstein
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Idiopathic pulmonary fibrosis (IPF) is an increasingly recognized, often fatal lung disease of unknown etiology.The aim of this study was to use whole-exome sequencing to improve understanding of the genetic architecture of pulmonary fibrosis.We performed a case-control exome-wide collapsing analysis including 262 unrelated individuals with pulmonary fibrosis clinically classified as IPF according to American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines (81.3%), usual interstitial pneumonia secondary to autoimmune conditions (11.5%), or fibrosing nonspecific interstitial pneumonia (7.2%). The majority (87%) of case subjects reported no family history of pulmonary fibrosis.We searched 18,668 protein-coding genes for an excess of rare deleterious genetic variation using whole-exome sequence data from 262 case subjects with pulmonary fibrosis and 4,141 control subjects drawn from among a set of individuals of European ancestry. Comparing genetic variation across 18,668 protein-coding genes, we found a study-wide significant (P < 4.5 × 10-7) case enrichment of qualifying variants in TERT, RTEL1, and PARN. A model qualifying ultrarare, deleterious, nonsynonymous variants implicated TERT and RTEL1, and a model specifically qualifying loss-of-function variants implicated RTEL1 and PARN. A subanalysis of 186 case subjects with sporadic IPF confirmed TERT, RTEL1, and PARN as study-wide significant contributors to sporadic IPF. Collectively, 11.3% of case subjects with sporadic IPF carried a qualifying variant in one of these three genes compared with the 0.3% carrier rate observed among control subjects (odds ratio, 47.7; 95% confidence interval, 21.5-111.6; P = 5.5 × 10-22).We identified TERT, RTEL1, and PARN-three telomere-related genes previously implicated in familial pulmonary fibrosis-as significant contributors to sporadic IPF. These results support the idea that telomere dysfunction is involved in IPF pathogenesis.
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.
Authors: Rowan Kuiper, Sophie L Corthals, Payman Hanifi-Moghaddam, Yvonne de Knegt, Henk Lokhorst, Hartmut Goldschmidt, Brian G M Durie, Brian G Van Ness, Gareth J Morgan, Mark van Duin, Herve Avet-Loiseau, Pieter Sonneveld
Journal: Blood (2009)
Value based healthcare
Authors: Muir Gray
Journal: BMJ (2017)

Reducing unwarranted variation to maximise the value of healthcare for populations

How can the gap between need and demand on the one hand and resources on the other be closed or even narrowed? Since the global financial collapse most countries have reduced or reversed annual increases in the resources invested in health services, creating a big problem for those who pay for or manage health services, many of whom are also clinicians.

The techniques that have been developed over the past 20 years include evidence based decision making (to ensure that only interventions with strong evidence of cost effectiveness are used), quality improvement (to improve outcomes), and cost reduction. These are all necessary but not sufficient. A new approach is emerging called value based healthcare, which aims to increase the value that is derived from the resources available for a population.

The Choosing Wisely campaign, led in the United Kingdom by the Academy of Medical Royal Colleges, has identified many interventions that could be substantially reduced without adverse effects on the population.1 The BMJ ’s leadership on overdiagnosis and “too much medicine” focuses more on the trend to overuse interventions that …
Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.
Authors: Sumanta Kumar Pal, Arun Azad, Sumeet Bhatia, Harry A. Drabkin, Brian Addis Costello, John Sarantopoulos, Ravindran Kanesvaran, Richard C. Lauer, Christopher Sweeney, Noah M. Hahn, Guru Sonpavde, Stephen Lane Richey, Timothy Breen, Gabriel Kremmidiotis, Annabell F. Leske, Elizabeth E. Doolin, David C. Bibby, Jeremy Andrew Simpson, Jose Luis Iglesias, Thomas E. Hutson
Journal: Journal of Clinical Oncology (2015)

475 Background: The vascular disrupting agent (VDA) BNC105P shows synergy with everolimus in preclinical models. The DisrupTOR-1 trial included a phase I component exploring this combination and a randomized phase II component comparing everolimus with BNC105P (Arm A) to everolimus monotherapy (Arm B) (Pal et al. ESMO 2014). Methods: Pts with clear cell mRCC and 1-2 prior therapies (including ≥1 VEGF-TKI) were randomized in the phase II study component. In Arm A, patients received a 7 day lead-in dose of everolimus followed by dosing with BNC105P. Patients in Arm A had optional blood collections prior to administration of BNC105P and 3 hours after receiving BNC105P. A fluorescence-based assay was used to characterize a broad panel of analytes at each time point. Biomarkers were assessed in both a static and dynamic fashion. For the former, biomarkers were stratified by median value, and progression-free survival (PFS) was compared in resulting subgroups using the Kaplan-Meier method. For the latter, change in biomarker level before and after BNC105P infusion was stratified by median difference, and PFS was compared in resulting subgroups using the Kaplan-Meier method. Results: 139 pts were randomized with 69 and 67 evaluable pts in Arms A and B, respectively. Dynamic biomarkers were assessed in a total of 44 patients who received everolimus with BNC105P. Increases in matrix metalloproteinase-9 (MMP-9) and stem cell factor (SCF) were associated with improved PFS (p=0.0421 and p=0.0291, respectively). Decreases in sex hormone binding globulin (SHBG) and serum amyloid protein (SAP) were associated with improved PFS (p=0.0184 and p=0.0063). With respect to static biomarkers, elevated baseline ferritin and lower baseline IL-8 were associated with improved PFS (p=0.0291 and p=0.0149, respectively). Conclusions: Several static and dynamic biomarkers in the DisrupTOR-1 trial were associated with PFS. A prospective biomarker-driven study examining everolimus with BNC105P selected by baseline IL-8 and ferritin is in development. Clinical trial information: NCT01034631.
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.
Authors: Xiaoying Jia, Xavier Leleu, Anne-Sophie Moreau, Evdoxia Hatjiharisi, Hai Ngo, Garrett O’Sullivan, Douglas McMillin, Steven Treon, Constantine Mitsiades, Teru Hideshima, Michael Palladino, Kenneth Anderson, Dharminder Chauhan, Irene Ghobrial
Journal: Blood (2006)
Cord Blood (CB) Bank Log CD34+ and CD34+ Subsets (CD38−, CD61+, CD90+) Are Significantly Correlated to Log Total CFU, CFU-GEMM, CFU-GM and BFU-E: A Report from the COBLT Program.
Authors: Mitchell S. Cairo, Elizabeth Wagner, Geoff Cohen, John Fraser, LeeAnn Jensen, Shelly Carter, Carmella van de Ven, Nancy A. Kernan, Joanne Kurtzberg
Journal: Blood (2004)
Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL).
Authors: Xianzheng Zhou, Xin Huang, Johnthomas Kang, Hongfeng Guo, Suet Choi, Preetinder Bassi, Tom C. Zhou, Michael C. Milone, Bruce L. Levine, Carl H. June, R. Scott McIvor, John E. Wagner, Bruce R. Blazar
Journal: Blood (2006)
Frontline Allogeneic and Autologous Hematopoietic Cell Transplant for Peripheral T-Cell Lymphomas (PTCLs): A Comparison Study Between Conventional Chemotherapy and Hematopoietic Cell Transplant from a Chinese Center
Authors: Haiwen Huang, Qiangli Wang, Ting Xu, Xiaochen Chen, Zhengming Jin, Wu Depei
Journal: Blood (2015)
Mechanisms of Defective Hydroxylation of 5-Methylcytosine in MDS Include Pathways Other Than TET2 and IDH1/2
Authors: Anna M Jankowska, Yun Huang, Myunggon Ko, Utz J Pape, Hideki Makishima, Hadrian Szpurka, Fabiola Traina, Valeria Visconte, Ramon V Tiu, Mikkael A Sekeres, Anjana Rao, Jaroslaw P Maciejewski
Journal: Blood (2011)
Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells
Authors: Seiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki
Journal: Blood (2011)
Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.
Authors: Eirini Katodritou, Evgenia Verrou, Anastasia Banti, Vassiliki Gastari, Dimitra Mihou, Christina Hadjiaggelidou, Dimitra Markala, Anna Lazaridou, Evangelos Terpos, Konstantinos Zervas
Journal: Blood (2007)
Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)
Authors: Barrans Sharon, Andrew J Davies, Ming Wang, Ming-Qing Du, Christoph Mamot, Keith Pugh, Josh Caddy, Matthew A Care, Jan Taylor, Reuben M Tooze, Tom Maishman, Louise Stanton, Debbie Hamid, Andrew McMillan, Paul Fields, Andrew Jack, Peter Johnson
Journal: Blood (2015)
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
Authors: Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J Verschure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci
Journal: Nature Genetics (2017)
T-Cell Depletion Is An Alternative Approach for Patients &gt;/= 55 Years Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Diseases
Authors: Erica Petrlik, Hugo Castro-Malaspina, Farid Boulad, Esperanza Papadopoulos, Ann A. Jakubowski
Journal: Blood (2010)
Improving Surgical Value and Culture Through Enhanced Recovery Programs
Authors: Lawrence Lee, Liane S. Feldman
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Hemojuvelin Acts as a Bone Morphogenetic Protein Co-Receptor To Regulate Hepcidin Expression.
Authors: Franklin W. Huang, Jodie L. Babitt, Diedra M. Wrighting, Tarek A. Samad, Yin Xia, Yisrael Sidis, Jason A. Campagna, Raymond T. Chung, Alan L. Schneyer, Clifford J. Woolf, Nancy C. Andrews, Herbert Y. Lin
Journal: Blood (2005)
Subjective assessment of cognitive function in the aging cancer patient: A URCC CCOP longitudinal study
Authors: S. Kohli, S. G. Fisher, C. E. Heckler, P. Jean-Pierre, S. G. Mohile, J. L. Wade III, R. Khanna, T. Banerjee, G. R. Morrow
Journal: Journal of Clinical Oncology (2008)

9631 Background: Unique challenges face elderly cancer survivors, including issues of quality of life. Impaired cognitive function is a common complaint among aging cancer patients. The purpose of this multicenter longitudinal study was to investigate the frequency and severity of self-reported problems with memory and concentration over time. Methods: Patients undergoing treatment for solid tumors self-rated problems with memory and concentration using an 11-point Likert Scale (0 = Not present to 10 = “As bad as you can imagine”) at baseline before treatment began (T1), at their worst during treatment (T2), and at 6 months following treatment (T3). Any symptom level ≥ 7 was classified as “severe.” Repeated measures analyses were used to examine differences in symptoms over time and between patients treated with and without chemotherapy. Results: Of 595 participants, 351 (59%) were aged ≤64 years and 244 (41%) were ≥65 years; 356 (60%) received chemotherapy, with or without radiation and 239 (40%) radiation alone. Concentration problems were reported by 40% (3% severe) of participants aged ≥65 at T1, 52% (7% severe) at T2 and 48% (4% severe) at T3. Memory loss was reported by 54% (3% severe) of participants aged ≥65 at T1, 58% (10% severe) at T2 and 59% (6% severe) at T3 (p < 0.0001). The average frequency and severity of both symptoms in patients receiving chemotherapy increased significantly between T1 and T2 (p<0.001). Both symptoms were less severe in patients receiving radiation alone at all three measurements (all ps<0.001). Symptoms at T3 were significantly higher than T1 for both groups (p<0.001) and all results were significantly worse when compared to those participants’ aged ≤64 (all ps<0.001). Conclusions: Self-reported problems with memory and concentration worsen with age in cancer patients undergoing chemotherapy and/or radiation. Prospective and objective assessments are needed to determine if cancer treatments are positively associated with cognitive decline, to identify the patients at risk, and to test appropriate interventions. Supported in part by a supplement from the Division of Cancer Control and Population Sciences, NCI, to Public Health Service grant U10 CA37420 and by NCI grant 1R25CA102618. No significant financial relationships to disclose.
Metabolism of Human Leukemia Cells in NOD/Scid Mice: Effectiveness of 2-Deoxy-D-Glucose
Authors: Norikazu Tsunekawa, Hiroshi Miwa, Shohei Mizuno, Mineaki Gotoh, Miyuki Takahashi, Mayuko Goto, Kazuto Suganuma, Ichiro Hanamura, Masato Shikami, Masakazu Nitta
Journal: Blood (2011)